CYP2C19
Cytochrome P450 2C19
Also known as: CP2CJ_HUMAN, CPCJ, CYP2C, P450IIC19
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P33261
- Gene
- CYP2C19
- Ensembl
- ENSG00000165841
- Chromosome
- 10
- Canonical length
- 490 aa
- Protein class
- Cancer-related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Vesicles
- Secretome location
- Intracellular and membrane
OverviewNCBI Gene
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize many xenobiotics, including the anticonvulsive drug mephenytoin, omeprazole, diazepam and some barbiturates. Polymorphism within this gene is associated with variable ability to metabolize mephenytoin, known as the poor metabolizer and extensive metabolizer phenotypes. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
490 residues, UniProt reviewed canonical sequence.
>P33261|CYP2C19
1 MDPFVVLVLC LSCLLLLSIW RQSSGRGKLP PGPTPLPVIG NILQIDIKDV SKSLTNLSKI
61 YGPVFTLYFG LERMVVLHGY EVVKEALIDL GEEFSGRGHF PLAERANRGF GIVFSNGKRW
121 KEIRRFSLMT LRNFGMGKRS IEDRVQEEAR CLVEELRKTK ASPCDPTFIL GCAPCNVICS
181 IIFQKRFDYK DQQFLNLMEK LNENIRIVST PWIQICNNFP TIIDYFPGTH NKLLKNLAFM
241 ESDILEKVKE HQESMDINNP RDFIDCFLIK MEKEKQNQQS EFTIENLVIT AADLLGAGTE
301 TTSTTLRYAL LLLLKHPEVT AKVQEEIERV IGRNRSPCMQ DRGHMPYTDA VVHEVQRYID
361 LIPTSLPHAV TCDVKFRNYL IPKGTTILTS LTSVLHDNKE FPNPEMFDPR HFLDEGGNFK
421 KSNYFMPFSA GKRICVGEGL ARMELFLFLT FILQNFNLKS LIDPKDLDTT PVVNGFASVP
481 PFYQLCFIPVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CYP2C19 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.22
- Highest tissue expression
- 178 nTPM
Expression across tissuesHPA
Tissue
- liver: 178 nTPM
- duodenum: 31 nTPM
- small intestine: 13 nTPM
- stomach: 2.8 nTPM
- esophagus: 2.2 nTPM
- gallbladder: 1.6 nTPM
Single-cell type
- hepatocytes: 85 nCPM
- enterocytes: 22 nCPM
- foveolar cells: 18 nCPM
- esophageal apical cells: 3.8 nCPM
- esophageal suprabasal cells: 3.4 nCPM
- cholangiocytes: 2.7 nCPM
Immune cell
- basophil: 0.4 nTPM
- neutrophil: 0.2 nTPM
- eosinophil: 0.1 nTPM
- memory B-cell: 0.1 nTPM
- naive B-cell: 0.1 nTPM
- NK-cell: 0.1 nTPM
Brain region
- cerebellum: 2 nTPM
- cerebral cortex: 1.9 nTPM
- hippocampal formation: 1.8 nTPM
- white matter: 1.8 nTPM
- basal ganglia: 1.7 nTPM
- choroid plexus: 1.7 nTPM
ReferencesPubMed · IEDB
Publications for CYP2C19 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
2 publications
- High levels of autoantibodies against drug-metabolizing enzymes in SLA/LP-positive AIH-1 sera.
2004 · Autoimmunity · RCR 0.2 · 6 citations - Autoantibodies against CYP-2C19: A Novel Serum Marker in Pediatric De Novo Autoimmune Hepatitis?
2017 · Biomed Res Int
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.87
- gnomAD pLI
- 0
- gnomAD missense Z
- -2.37
- DepMap mean gene effect
- 0.06
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- epoxygenase P450 pathway
- long-chain fatty acid metabolic process
- monoterpenoid metabolic process
- omega-hydroxylase P450 pathway
- steroid metabolic process
- xenobiotic catabolic process
- xenobiotic metabolic process
Molecular functions
- (R)-limonene 6-monooxygenase activity
- (S)-limonene 6-monooxygenase activity
- (S)-limonene 7-monooxygenase activity
- enzyme binding
- heme binding
- iron ion binding
- long-chain fatty acid omega-1 hydroxylase activity
- monooxygenase activity
- oxidoreductase activity
- oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- oxygen binding
- steroid hydroxylase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CYP2C19 as an antibody target. Whether an autoantibody or antibody against CYP2C19 could matter depends on whether native CYP2C19 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CYP2C19 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label CYP2C19 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...